Bryn Mawr Capital Management LLC Buys 46,531 Shares of Amgen Inc. (NASDAQ:AMGN)

Bryn Mawr Capital Management LLC grew its holdings in Amgen Inc. (NASDAQ:AMGN - Free Report) by 365.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 59,260 shares of the medical research company's stock after purchasing an additional 46,531 shares during the quarter. Bryn Mawr Capital Management LLC's holdings in Amgen were worth $15,446,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Capital Performance Advisors LLP purchased a new position in shares of Amgen during the third quarter valued at approximately $25,000. Legacy Investment Solutions LLC acquired a new stake in Amgen during the 3rd quarter valued at $29,000. Heck Capital Advisors LLC acquired a new stake in Amgen during the 4th quarter valued at $36,000. PrairieView Partners LLC grew its holdings in Amgen by 118.3% during the 4th quarter. PrairieView Partners LLC now owns 179 shares of the medical research company's stock valued at $46,000 after purchasing an additional 97 shares in the last quarter. Finally, Bank of Jackson Hole Trust acquired a new stake in Amgen during the 4th quarter valued at $50,000. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Amgen Trading Up 2.1 %

Shares of Amgen stock traded up $6.40 during trading on Friday, hitting $304.33. The stock had a trading volume of 1,792,375 shares, compared to its average volume of 3,075,920. The stock has a 50 day simple moving average of $275.62 and a 200 day simple moving average of $300.75. The company has a market capitalization of $163.49 billion, a PE ratio of 40.25, a P/E/G ratio of 2.55 and a beta of 0.56. The company has a quick ratio of 0.95, a current ratio of 1.26 and a debt-to-equity ratio of 9.62. Amgen Inc. has a 1 year low of $253.30 and a 1 year high of $346.85.

Amgen (NASDAQ:AMGN - Get Free Report) last posted its quarterly earnings results on Tuesday, February 4th. The medical research company reported $5.31 EPS for the quarter, topping the consensus estimate of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. On average, research analysts expect that Amgen Inc. will post 20.6 EPS for the current fiscal year.

Amgen Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, February 14th will be issued a dividend of $2.38 per share. This is a boost from Amgen's previous quarterly dividend of $2.25. This represents a $9.52 annualized dividend and a dividend yield of 3.13%. The ex-dividend date is Friday, February 14th. Amgen's dividend payout ratio (DPR) is currently 126.09%.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the stock. Citigroup decreased their price objective on shares of Amgen from $310.00 to $295.00 and set a "neutral" rating for the company in a report on Tuesday, January 28th. Wells Fargo & Company cut their price objective on shares of Amgen from $335.00 to $280.00 and set an "equal weight" rating on the stock in a research report on Friday, January 10th. Leerink Partners cut their price objective on shares of Amgen from $349.00 to $302.00 in a research report on Wednesday, November 27th. UBS Group cut their price objective on shares of Amgen from $335.00 to $326.00 and set a "neutral" rating on the stock in a research report on Thursday, October 31st. Finally, Jefferies Financial Group restated a "buy" rating and set a $380.00 price target on shares of Amgen in a research report on Tuesday, November 12th. Two research analysts have rated the stock with a sell rating, ten have given a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $314.09.

Insider Buying and Selling

In other Amgen news, EVP Jonathan P. Graham sold 25,045 shares of Amgen stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $293.12, for a total value of $7,341,190.40. Following the completion of the sale, the executive vice president now directly owns 28,987 shares in the company, valued at $8,496,669.44. The trade was a 46.35 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Nancy A. Grygiel sold 1,589 shares of Amgen stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total transaction of $483,802.83. Following the completion of the sale, the senior vice president now owns 7,210 shares of the company's stock, valued at $2,195,228.70. This trade represents a 18.06 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 35,405 shares of company stock worth $10,410,596. 0.69% of the stock is owned by company insiders.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.